174311-79-6 Usage
General Description
1H-Indole-7-carboxylic acid, 6-amino-, ethyl ester (9CI) is a chemical compound belonging to the class of organic compounds known as indoles, which are aromatic heterocyclic compounds with a bicyclic structure. This specific compound features an ethyl ester functional group, which suggests that it is derived from the condensation of an acid (in this case, 1H-Indole-7-carboxylic acid) and an alcohol (in this case, ethanol), and a 6-amino modification on its core indole structure. The "1H" in its name indicates the presence of a hydrogen atom, while "7-carboxylic acid" indicates the presence of a carboxylic acid group at the 7th position in the indole ring. The "9CI" designation implies that this substance is listed in the ninth collective index, suggesting it is a synthetic, rather than naturally occurring, compound. However, the uses and characteristics of this particular compound are not widely documented in existing chemical literature.
Check Digit Verification of cas no
The CAS Registry Mumber 174311-79-6 includes 9 digits separated into 3 groups by hyphens. The first part of the number,starting from the left, has 6 digits, 1,7,4,3,1 and 1 respectively; the second part has 2 digits, 7 and 9 respectively.
Calculate Digit Verification of CAS Registry Number 174311-79:
(8*1)+(7*7)+(6*4)+(5*3)+(4*1)+(3*1)+(2*7)+(1*9)=126
126 % 10 = 6
So 174311-79-6 is a valid CAS Registry Number.
InChI:InChI=1/C11H12N2O2/c1-2-15-11(14)9-8(12)4-3-7-5-6-13-10(7)9/h3-6,13H,2,12H2,1H3
174311-79-6Relevant articles and documents
Compositions for Treatment of Cystic Fibrosis and Other Chronic Diseases
-
, (2015/09/22)
The present invention relates to pharmaceutical compositions comprising an inhibitor of epithelial sodium channel activity in combination with at least one ABC Transporter modulator compound of Formula A, Formula B, Formula C, or Formula D. The invention also relates to pharmaceutical formulations thereof, and to methods of using such compositions in the treatment of CFTR mediated diseases, particularly cystic fibrosis using the pharmaceutical combination compositions.
COMPOSITIONS FOR TREATMENT OF CYSTIC FIBROSIS AND OTHER CHRONIC DISEASES
-
, (2012/04/23)
The present invention relates to pharmaceutical compositions comprising an inhibitor of epithelial sodium channel activity in combination with at least one ABC Transporter modulator compound of Formula A, Formula B, Formula C, or Formula D. The invention also relates to pharmaceutical formulations thereof, and to methods of using such compositions in the treatment of CFTR mediated diseases, particularly cystic fibrosis using the pharmaceutical combination compositions.
Concise syntheses of the novel 1H-pyrrolo[3,2-g]quinazoline ring system and its [2,3-f] angular isomer
Showalter, H. D. Hollis,Sun, Li,Sercel, Anthony D.,Winters, R. Thomas,Denny, William A.,Palmer, Brian D.
, p. 1155 - 1158 (2007/10/03)
-